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Background: Intracerebral administration of the angiotensin II type 2 receptor (AT2R) agonist, CGP42112, is
neuroprotective in a rat model of ischemic stroke. To explore further its possible cellular target(s) and therapeutic
utility, we firstly examined whether CGP42112 may exert direct protective effects on primary neurons following
glucose deprivation in vitro. Secondly, we tested whether CGP42112 is effective when administered systemically in a
mouse model of cerebral ischemia.
Methods: Primary cortical neurons were cultured from E17 C57Bl6 mouse embryos for 9 d, exposed to glucose
deprivation for 24 h alone or with drug treatments, and percent cell survival assessed using trypan blue exclusion.
Ischemic stroke was induced in adult male C57Bl6 mice by middle cerebral artery occlusion for 30 min, followed by
reperfusion for 23.5 h. Neurological assessment was performed and then mice were euthanized and infarct and
edema volume were analysed.
Results: During glucose deprivation, CGP42112 (1x10-8 M and 1x10-7 M) reduced cell death by ~30%, an effect that
was prevented by the AT2R antagonist, PD123319 (1x10
-6 M). Neuroprotection by CGP42112 was lost at a higher
concentration (1x10-6 M) but was unmasked by co-application with the AT1R antagonist, candesartan (1x10
-7 M). By
contrast, Compound 21 (1x10-8 M to 1x10-6 M), a second AT2R agonist, had no effect on neuronal survival. Mice
treated with CGP42112 (1 mg/kg i.p.) after cerebral ischemia had improved functional outcomes over
vehicle-treated mice as well as reduced total and cortical infarct volumes.
Conclusions: These results indicate that CGP42112 can directly protect neurons from ischemia-like injury in vitro via
activation of AT2Rs, an effect opposed by AT1R activation at high concentrations. Furthermore, systemic
administration of CGP42112 can reduce functional deficits and infarct volume following cerebral ischemia in vivo.
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Stroke is the world’s second most common cause of
death and a leading cause of long-term disability in
adults [1]. Currently, there are very few safe and effective
treatment options available for patients following stroke
[2] and hence there is a great need to develop new ther-
apies that may improve stroke outcome. It is conceivable* Correspondence: chris.sobey@monash.edu
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reproduction in any medium, provided the orthat targeting elements of the renin-angiotensin system
(RAS) may provide neuroprotection prior to and/or fol-
lowing stroke [3-11].
The major peptide of the RAS is angiotensin II (Ang
II), which acts with equal affinity at two membrane-
bound receptors, the angiotensin type 1 receptor (AT1R)
and the type 2 receptor (AT2R). It is well established that
excessive stimulation of the AT1R by Ang II mediates
biologically detrimental actions in the setting of cerebro-
vascular disease [3,12-14], whereas activation of the
AT2R may at least partly offset the effects of AT1R. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[15]. In addition, blockade of the AT1R may be protect-
ive at least in part because it results in greater binding
to and activation of the AT2R by Ang II [3-5]. A number
of clinical trials have demonstrated the beneficial effects
of sartan class drugs (AT1R antagonists) such as cande-
sartan and eprosartan, given prior to and following
stroke [16,17].
The AT2R is the predominant angiotensin receptor
subtype expressed in fetal organs, and its expression is
downregulated following birth [9,18]. Interestingly, re-
cent studies have shown that under pathological condi-
tions such as ischemic insult, AT2R expression may be
upregulated [7,9] and it may play an important role in
the growth, repair and regeneration of neuronal tissue.
To date only one study has tested for a neuroprotec-
tive effect of direct AT2R activation using a selective
AT2R agonist in the setting of stroke, and it suggested
that direct AT2R activation is beneficial during ischemic
stroke in spontaneously hypertensive rats subjected to
cerebral ischemia [8]. Specifically, intracerebral adminis-
tration of the AT2R agonist, CGP42112, prior to ische-
mia resulted in a reduced infarct volume at 72 h [8].
This protective effect of CGP42112 was abolished by ad-
ministration of PD123319 (an AT2R antagonist), con-
firming a role for AT2R. In the brain, AT2Rs are known
to be expressed in neurons [7] and also in vascular cells
[5], although the target cell types for the protective ac-
tion of CGP42112 remain unknown.
In the present study, we firstly tested the hypothesis
that selective AT2R activation is directly neuroprotective
in vitro using primary cortical neuron cultures deprived
of glucose. Secondly, we tested whether CGP42112 may
be effective in limiting neurological deficit when admi-
nistered systemically following cerebral ischemia in a
mouse model of stroke.
Materials and methods
Animals
All animal experiments were performed in accordance
with the National Health and Medical Research Council
of Australia guidelines, and with approval from the
Monash University Animal Ethics Committee (Projects
SOBSB/2010/34 and SOBSB/2009/55). Thirteen preg-
nant C57BL6/J (Monash Animal Research Platform)
females were used to obtain cortical neurons from E17
pups. For cerebral ischemia-reperfusion (I/R) experi-
ments in vivo, we used a total of 40 male C57BL/6 mice
(8-12 weeks old; weight = 26 ± 6g). Five mice were
excluded from the study when, during the surgical pro-
cedure to induce cerebral ischemia-reperfusion: (1) there
was inadequate (<70%) reduction in regional cerebral
blood flow (rCBF) (n = 2); or (2) no measured increase in
blood flow at reperfusion after 30 min ischemia (n = 1);or (3) animals died before 24 h of reperfusion had
elapsed (n = 2).
Primary neuronal cultures
Mouse primary cortical neurons were prepared as previ-
ously described [19] with some modifications. Timed
pregnant mice were anesthetized using inhaled isoflur-
ane and an incision was made in the abdominal wall to
remove embryos, which were immediately placed and
dissected in Hank’s balanced salt solution (HBSS) (Invi-
trogen, Melbourne) without Ca2+ and Mg2+, supplemen-
ted with HEPES (10 mmol/L) (Invitrogen, Melbourne),
gentamicin (5mg/L) (Invitrogen, Melbourne). Dissected
cortices (free of meninges) were digested in trypsin (1
mg/ml) (Sigma, Sydney) for 10 min at room
temperature, neutralized with trypsin inhibitor (Sigma,
Sydney) for 10 min, and washed three times with Neuro-
basal medium (NBM) (Invitrogen, Melbourne) supple-
mented with L-glutamine (2 mmol/L), gentamycin (5
mg/L), and B-27 supplements (Invitrogen, Melbourne)
pH 7.2. Dissociated cell suspensions were resuspended
in NBM (+ supplements) then dispensed into poly-D-
lysine (Sigma, Sydney) coated 60-mm2 Petri dishes. Cells
were incubated overnight at 37 °C in a humidified at-
mosphere of 5% CO2 in air. Medium was replaced with
fresh NBM (+ supplements), and the cells were main-
tained for a further 8 d without renewal of the medium.
Glucose deprivation
Glucose deprivation was used to induce slow cell death
through apoptotic mechanisms, analogous to the post-
ischemic neuronal death that occurs in the penumbra
region surrounding an infarct core in vivo [20-22]. For
glucose deprivation, cultured neurons (9 d in vitro) were
incubated in glucose-free Locke’s medium containing (in
mmol/L) NaCl 154.0, KCl 5.6, CaCl22H2O 2.3,
MgCl26H2O 1.0, NaHCO3 3.6, HEPES 5.0, pH 7.2, sup-
plemented with gentamicin (5 mg/L) at 37 °C in a hu-
midified atmosphere of 5% CO2 in air for 24 h. For drug
treatments, cells were exposed to one or more of the fol-
lowing: CGP42112 (1x10-8, 1x10-7 or 1x10-6 M; GLS
Biochem, Shanghai); PD123319 (1x10-6 M; Sigma, Syd-
ney); Compound 21 (1x10-8, 1x10-7 or 1x10-6 M; kindly
provided by A. Hallberg, Department of Medicinal
Chemistry, Uppsala University, Sweden); or candesartan
(1x10-7 M; Astrazeneca, Sweden). All drugs were dis-
solved and diluted in distilled water.
Cell viability assay
Cell viability was determined by trypan blue exclusion.
In brief, cells were incubated at 37°C in 0.2% trypan blue
for 15 min. After washing three times with phosphate
buffered saline (PBS; pH 7.4), cells were fixed with 4%
paraformaldehyde for 10 min. Twenty images of random
AB
C
Figure 1 Mean percentage neuronal cell death. A. Data are
shown for cells exposed to normal conditions (NC) or glucose
deprivation with vehicle for 24 h (GD). Other cells exposed to GD
were treated with CGP42112 at 1x10-8 M (CGP-8), 1x10-7 M (CGP-7),
1x10-6 M (CGP-6) (n = 8) (*P< 0.05 vs. NC). B. Data are shown for cells
exposed to normal conditions (i.e. 24 h NC) or glucose deprivation
with vehicle (24 h GD) or 3 concentrations of CGP42112 in the
presence of PD123319 at 1x10-6 M (PD-6). Data for GD with
PD123319 alone (n = 6) are also shown (*P< 0.05 vs. vehicle; NS
P > 0.05 vs. vehicle). C. Data are shown for cells exposed to normal
conditions (NC) or glucose deprivation (GD) with vehicle (24 h GD)
or 1x10-6 M CGP42112 (CGP-6) in the absence or presence of
1x10-7 M candesartan (CV-7) (n = 7; *P< 0.05 vs. vehicle).
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using an inverted microscope and camera (Nikon,
Japan) and associated computer software NIS-elements
version 3.0 (Nikon, Japan). Approximately one thou-
sand cells were counted from each dish. Cell viability
was determined based on colour, size and cellular
morphology by an experimenter blinded to the treat-
ment group, and the cell death occurring during the
24 h glucose deprivation period was calculated.
Cerebral ischemia-reperfusion in vivo
We used a model of focal cerebral ischemia-reperfusion
similar to that described previously [23,24]. Briefly, mice
were anesthetized with a mixture of ketamine (80 mg/kg
i.p.) and xylazine (10 mg/kg i.p.). A midline neck inci-
sion was made, and the right external carotid (ECA) and
pterygopalatine arteries were isolated and cauterized.
The internal carotid artery (ICA) was lifted and occluded
at the peripheral site of the bifurcation of the ICA. Focal
cerebral ischemia was induced by intraluminal filament
occlusion for 30 min of the right middle cerebral artery
(MCA) with a 6-0 nylon monofilament with a silicone-
coated tip (0.20-0.22 mm, Doccol Co., Redlands, CA,
USA). Severe (~75%) reduction in rCBF was confirmed
using trans-cranial laser-Doppler flowmetry (Perimed) in
the area of cerebral cortex supplied by the MCA (~2
mm posterior and ~5 mm lateral to bregma). Mice were
treated i.p. with either vehicle (saline; n = 16) or
CGP42112 (1 mg/kg; n = 19) at the commencement of
reperfusion.
Neurological assessment and quantification of
infarct volume
Neurological deficit was evaluated using a five-point
scoring system (0, no deficit; 1, failure to extend right
paw; 2, circling to the right; 3, falling to the right; and 4,
unable to walk spontaneously) and hanging wire test in
a blinded fashion, as described previously [23-26].
Briefly, mice were suspended from a 30 cm high wire by
their forelimbs for up to 60 s. Average hanging time (i.e.
AB
Figure 2 Mean percentage neuronal cell death. A. Data are
shown for cells exposed to normal conditions (NC) or glucose
deprivation with vehicle for 24 h (GD). Other cells exposed to GD
were treated with Compound 21 at 1x10-8 M (C21-8), 1x10-7 M
(C21-7), 1x10-6 M (C21-6) (n = 6) (NS P> 0.05 vs. vehicle). B. Cells
were treated with Compound 21 in the presence of 1x10-6 M





Figure 3 Regional cerebral blood flow (rCBF) and neurological
function in vehicle- and CGP42112-treated mice. Data for rCBF
(A), neurological deficit score (B) and hanging-wire test (C) are
shown for animals 24 h following cerebral ischemia and treatment
with either vehicle (Veh; n = 16) or CGP42112 (n = 19; *P< 0.05 vs.
vehicle).
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recorded. Cerebral infarct distribution and volumes of
infarct and edema were also estimated as described pre-
viously [23,24].
Double-label fluorescent immunohistochemistry
Serial coronal sections (10 μm thick) were collected for
analysis. Brain sections were fixed in acetone for 15 min
and washed in 0.01 M phosphate-buffered saline (PBS,
3 x10 min). Sections were blocked with 10% goat serum
(Abcam) for 30 min then incubated overnight in anti-
rabbit active Caspase 3 (1:200; Abcam) and anti-mouse
NeuN (1:1000; Chemicon). Following several washes in
PBS (3 x 10 min), sections were incubated with Alexa
594-conjugated anti-rabbit IgG (1:500; invitrogen) for 2 h
in room temperature. Brain sections were then washedwith PBS (3 x 5 min) and incubated in M.O.M Biotiny-
lated anti-mouse IgG Reagent (Vector Laboratories) for
10 min. Sections were then again washed in PBS (2 x 2
min) and Fluorescein Avidin DCS (Vector Laboratories)
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10 min) and cover-slipped. Staining was analysed on an
Olympus fluorescence/light microscope (Olympus,
Hamburg, Germany).
Data analysis
Results are reported as the mean ± standard error (SEM).
Statistical differences (P < 0.05) were determined by one-
way analysis of variance (ANOVA) with Dunnett’s post-
hoc test or an unpaired t-test, as appropriate, using
GraphPad Prism version 5 (Graph Pad Software Inc.,
San Diego, CA).
Results
Effects of AT2R agonists on death of primary cortical
neurons during glucose deprivation
Following exposure of primary cortical neurons to 24 h
of glucose deprivation, cell death was markedly
enhanced (~35-40%; see Figures 1, 2, 3). Treatment with
the AT2R agonist CGP42112 (1x10
-8 or 1x10-7 M)
resulted in a ~30% reduction in cell death due to glucose
deprivation, whereas a higher concentration of
CGP42112 (1x10-6 M) had no protective effect
(Figure 1A). The protection by 1x10-8 M and 1x10-7 M
CGP42112 was prevented by co-treatment with theA
CB
Veh
Figure 4 Total brain infarct and edema volume in vehicle- (Veh; n = 1
Images of representative coronal brain sections from vehicle- (left) and CGP
volume (B) and brain edema volume (C).AT2R antagonist PD123319 (1x10
-6 M; Figure 1B). Pro-
tection by 1x10-6 M CGP42112 was unmasked by co-
treatment with the AT1R antagonist candesartan (1x10
-7
M; Figure 1C). In contrast to the effect of CGP42112,
the putative AT2R agonist Compound 21 (1x10
-8 to
1x10-6 M) exerted no effects on cell death induced by
glucose deprivation (Figure 2A-B).
Effect of systemic administration of CGP42112 on
outcome following ischemic stroke
Vehicle or CGP42112 was injected at the time of reper-
fusion in all mice. Cerebral blood flow profiles were
similar between the two groups of mice during the 30
min of middle cerebral artery occlusion and by the end
of the 30 min recording period following reperfusion
(Figure 3A). However, compared with vehicle treatment,
blood flow was transiently but significantly higher in
CGP42112-treated mice during the first 10 min of reper-
fusion (Figure 3A). Mice treated with CGP42112 also
exhibited a significant improvement in functional out-
comes at 24 h as measured using a neurological deficit
score and by hanging wire time (Figure 3B-C). In
addition, total and cortical infarct volumes in mice trea-
ted with CGP42112 were significantly reduced compared
with vehicle-treated mice. (Figures 4 and 5). EdemaCGP
6) and CGP42112-treated mice (n = 19; *P<0.05 vs. vehicle). A.




Cortical Infarct Volume Cortical Infarct Distribution
Subcortical Infarct Volume Subcortical Infarct Distribution
Figure 5 Cortical (A-B) and subcortical (C-D) brain infarct volume and distribution in vehicle- (Veh; n = 16) and CGP42112-treated mice
(n = 19; *P<0.05 vs. vehicle).
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vehicle-treated mice (Figure 4D).
Effect of CGP42112 on neuronal apoptosis in vivo
Finally, we performed a small number of studies
(4 vehicle-treated and 4 CGP42112-treated mice) to as-
sess whether the neuroprotective effects of CGP42112
following stroke may be associated with attenuated
neuronal apoptosis in vivo. For this, we utilised double-
labelling immunohistochemistry for cells staining
positive for cleaved/activated caspase 3 and NeuN (the
neuronal marker). In each mouse brain, we counted be-
tween 600 and 3600 cells in 9 sections of somatosensory
cortex (bregma +1.18 to -2.18 mm) at 200x magnifica-
tion. Cleaved/activated Caspase 3 immunoreactivity was
present in at least some sections from each of the
vehicle-treated mice, at a frequency of 3.43 ± 1.03% of the
6,154 NeuN-positive cells counted. By contrast, no
immunoreactivity for cleaved caspase 3 was detectable in
any of the 36 sections, containing 5,709 NeuN-positive
cells counted from CGP42112-treated mice (i.e.
0.00 ± 0.00%; p = 0.06 versus vehicle, n = 4, Wilcoxonsigned rank test, GraphPad Prism). These preliminary
data suggest that the post-stroke protection afforded by
CGP42112 in vivo is associated with reduced neuronal
apoptosis.Discussion
There are three new major findings of the present study.
First, CGP42112, an AT2R agonist, exerts direct protect-
ive effects on primary neurons in culture to reduce
cell death following exposure to glucose deprivation,
an effect which was blocked by an AT2R antagonist,
PD123319. Second, at a high concentration of
CGP42112 (1x10-6 M), its protective effects are lost due
to additional activation of AT1R, and this effect can be
prevented with the AT1R antagonist, candesartan. Third,
systemic administration of CGP42112 at the time of
reperfusion following cerebral ischemia in mice results
in substantially less neurological deficit and infarct vol-
ume at 24 h. Together, these results suggest that the
neuronal AT2R is a valid therapeutic target for treatment
following ischemic stroke and that CGP42112 can be
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about functional benefits.
We have previously reported that pretreatment with
CGP42112 can limit infarct volume following cerebral
ischemia in spontaneously hypertensive rats when
injected intracerebrally into the region to be subjected
to ischemia [8]. It is unknown what cell type(s) might be
the target for such protective effects of CGP42112
in vivo. The use of primary neuronal cultures in this
study has thus enabled us to evaluate whether
CGP42112 might potentially have a direct protective ef-
fect on neurons subjected to ischemia-like conditions.
Indeed, we found that this AT2R agonist (at 1x10
-8 M
and 1x10-7 M) can modestly protect neurons from such
cell death. Our findings are analogous to those of Li
et al. (2005) [7] whereby AT2R stimulation with Ang II
significantly increased viability of cultured neurons sub-
jected to glutamate-induced neuronal injury.
Interestingly, the neuroprotective effect of CGP42112
was lost at the highest concentration tested (i.e. 1x10-6
M). Incomplete selectivity of CGP42112 for the AT2R
over the AT1R has been noted at high concentrations
[27]. There is good evidence that activation of the AT1R
may contribute to the pathology of stroke [15], as well
as glutamate-induced neuronal injury [7]. We found evi-
dence that the activation of neuronal AT1R by 1x10
-6 M
CGP42112 overides its AT2R-dependent neuroprotec-
tion, in that this high concentration of CGP42112
was protective if co-administered with the AT1R
antagonist, candesartan. Such data support the notion
that therapeutic effectiveness of AT2R agonists
may be greater when co-administered with an AT1R
antagonist [15].
Unlike CGP42112, we found no evidence for any pro-
tective effect by a similar range of concentrations of
Compound 21. This drug, which is reported to be an or-
ally active non-peptidic AT2R agonist, has been shown
to have ~10-fold lower affinity than CGP42112 at the
AT2R [28]. It is therefore possible that higher concentra-
tions may have been required in the present study to
sufficiently activate AT2R to provide protection.
Systemic administration of CGP42112, commencing at
reperfusion, resulted in a markedly improved functional
outcome and reduced infarct volume, particularly in the
cortical region at 24 h following transient cerebral ische-
mia in mice. This finding is analogous to the above-
mentioned study of McCarthy et al. who found that
intracerebral injection of CGP42112 prior to cerebral is-
chemia exerted neuroprotective effects in the cortex [8].
The fact that systemic administration of CGP42112
achieved significant functional benefits associated with
reductions in infarct volume and neuronal apoptosis
suggests that movement of the drug across the blood-
brain barrier was effective. Thus, the present workadvances the concept that administration of an AT2R
agonist at the time of tissue plasminogen activator-
induced reperfusion is plausible as a combination treat-
ment in stroke patients with successful post-ischemic
reperfusion therapy. Further studies are required to test
whether an AT2R agonist might also be protective fol-
lowing permanent cerebral ischemia (i.e. without reper-
fusion). Interestingly, CGP42112 treatment had no
significant effect on infarct at subcortical regions or
edema volumes at 24 h. It is possible that the clear bene-
ficial effects of CGP42112 on functional outcome mea-
sures include facilitation of neuronal activity [7,29] as
well as simply preventing neuronal death. Future studies
to clarify the extent of protection by CGP42112 treat-
ment at later timepoints and also at different doses are
warranted.
While our results suggest that AT2R located on neu-
rons could mediate protective effects of CGP42112 in
ischemia-like conditions, there are a number of other
cell types which may participate in the AT2R-mediated
neuroprotection observed in vivo. In particular, the
AT2R located on endothelial cells could play an import-
ant role in AT2R-mediated neuroprotection following
stroke by supporting cerebral blood flow via
endothelium-dependent vasodilatation [30]. Consistent
with this possibility, we found that blood flow velocity in
the cortical region impacted by cerebral artery occlusion
was transiently higher early during reperfusion in ani-
mals treated with CGP42112. It remains to be deter-
mined whether non-neuronal brain cells, such as
astrocytes and oligodendrocytes, might also express
AT2R that contribute to improved functional outcome
following CGP42112 treatment [31]. Furthermore, Iwa-
nami et al. (2011) have recently demonstrated that AT2R
located on haematopoietic cells may be a target for
achieving neuroprotection following stroke [6]. Elucidat-
ing the contribution of multiple cell types involved in
AT2R-mediated neuroprotection would aid in a better
understanding of the neuroprotective potential of AT2R
agonists in vivo.
It is important to note that we cannot fully exclude
the possibility that infarct volume was still not fully
developed at 24 h in this study, and thus it is possible
that the protective effect of CGP42112 after stroke
in vivo represented a delay in injury development rather
than a complete prevention of it. While we have previ-
ously found that infarct volume is no greater at 72 h
than at 24 h after 30 min of middle cerebral artery oc-
clusion in C57Bl6 mice [23], a definitive conclusion
regarding the sustained protection by CGP42112 cannot
be made without a longer timepoint being studied.
In summary, the present study provides evidence that
AT2R activation by the agonist CGP42112 can both dir-
ectly protect against neuronal cell death following
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comes in association with reduced infarct volume when
administered systemically following cerebral ischemia-
reperfusion in vivo. Overall, the findings support the hy-
pothesis that administration of an AT2R agonist could
be a useful adjunct in the clinical treatment of acute
stroke.
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